Variantyx and FDNA Announce Integration of their Applications to Facilitate Rare Disease Diagnosis

FRAMINGHAM, Mass. & BOSTON–(BUSINESS WIRE)–Variantyx (www.variantyx.com) today announced the integration of its clinical whole genome testing pipeline with FDNA’s (www.fdna.com) Face2Gene suite of applications. Using its proprietary Genomic Intelligence^® platform, Variantyx provides end-to-end clinical diagnostic services for rare genetic disorders based on comprehensive whole genome sequencing (WGS). Integration with Face2Gene technology now enables clinicians worldwide to send information about the phenotypes, syndromes, and genes that correlate with a patient’s facial and clinical analysis to Variantyx directly, speeding analysis and improving variant interpretation.